In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. By Tina Bellon and Nate Raymond. Income tax benefit was approximately $510 million despite pre-tax earnings of $1.9 billion in the quarter primarily due to the impact of internal transfers of certain intangible assets of $1.0 billion. 0000007493 00000 n The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. 0000043107 00000 n Whether its bringing more than a dozen key medicines to market since 2009, or expanding patient access to medicine, our commitment to patients inspires us and guides our actions as responsible corporate citizens. 0000042754 00000 n We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Learn more! Employees must meet all eligibility requirements in order to qualify. Your response will be removed from the review this cannot be undone. In addition, the financial guidance provided in this release relies on assumptions about the duration and severity of the COVID-19 pandemic, timing of the return to a more stable business environment, patient and physician behaviors, buying patterns and clinical trial activities, which may prove to be incorrect. ,,M|L7^`kBQv# |88960\epmPZyC?r= ,L*P}``rN Drug Discovery and Translational Medicine, Equal Employment Opportunity / Disability Assistance. With support and coaching from your colleagues, youre encouraged to take on stretch assignments that maximize your learning experience. Normal for industry. Also note that a reconciliation of the forward-looking revenue (ex-FX), free cash flow and non-GAAP operating margin measures is not provided due to the inherent difficulty in forecasting and quantifying items that are necessary for such reconciliation. NEW YORK--(BUSINESS WIRE)-- Find out why possibility lives at Bristol Myers Squibb, We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues, We pursue disruptive and bold solutions for patients, We move together with speed and quality because patients are waiting, Our dedication to learning and excellence helps us to deliver exceptional results, We all own BMS success and strive to be transparent and deliver on our commitments, We embrace diversity and foster an environment where we can all work together at our full potential. Our Insights for Success program is offered to diverse employees to enhance their organizational and personal career success and ensure equitable leadership throughout the company. None of our operations have been identified as having significant risk for incidents of child labor or forced labor. 0000012578 00000 n Our work is challenging and you shouldn't have to go it alone. Bristol-Myers Squibb is a multinational pharmaceutical company headquartered in New York City. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the companys business and market, particularly those identified in the cautionary statement and risk factors discussion in the companys Annual Report on Form 10-K for the year ended December 31, 2020, as updated by the companys subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. Your response will be removed from the review this cannot be undone. Celestica - Ireland. Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Wednesday, April 28th. rotating shift 36/48, which involves working all holidays that fall on the schedule. Goldman Sachs & Co. LLC is serving as the exclusive financial advisor to Turning Point Therapeutics, and Cooley LLP is serving as legal counsel. BMY: Get the latest Bristol-Myers Squibb stock price and detailed information including BMY news, historical charts and realtime prices. Gregorian year (common era) Hebrew year. We incorporate security and human rights in our assessment of countries when determining where to locate operating facilities. 0000001396 00000 n 0000007092 00000 n We believe in a Total Rewards experience that enriches your life today and engages and empowers you to save, perform, grow, and build toward all of your tomorrows. We expect our contractors and suppliers to comply with all legal and regulatory requirements for the workplace, including health and safety, diversity and human rights. A cash dividend payment of $0.49 per share is scheduled to be paid on August 02, 2021. Tuition reimbursement is available to eligible employees who, through their own initiation and desire for development, participate in accredited educational programs that their manager deems will be mutually beneficial to BMS and the employee. Japan's Ministry of Health, Labour and Welfare also accepted the NDA for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis, pustular psoriasis and erythrodermic psoriasis. . And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication. The same period a year ago included license and acquisition charges related to Dragonfly, an in-process research and development (IPR&D) impairment charge and cash settlement of MyoKardia unvested stock awards. The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the companys baseline performance, supplement or enhance management, analysts and investors overall understanding of the companys underlying financial performance and trends and facilitate comparisons among current, past and future periods. View this presentation. For your convenience, specialized Bristol Myers Squibb representatives are available by phone or email to help you with your medical, technical, or general inquiries. Bristol-Myers is Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: 21-04897. 0000003811 00000 n Shareholders. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. The study was conducted by The Bristol Myers Squibb-Janssen Collaboration. 0000015083 00000 n 0000004898 00000 n ET during which company executives will review financial information and address inquiries from investors and analysts. Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Barclays Virtual Global Healthcare Conference, which will Shares of Bristol Myers Squibb Co. BMY, -0.22% sank 0.22% to $66.77 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX, Glassdoor is your resource for information about the Vacation & Paid Time Off benefits at Bristol Myers Squibb. Aug 2010 - Present12 years 8 months. customer.relations@bms.com (877) 517-6326 (Monday-Friday, 8 AM-8 PM ET) Adverse event or product quality complaints (800) 721-5072 0000003660 00000 n Our expansive library of resources covers a wide range of special interest topics in multiple languages through a variety of top learning and development resources powered by LinkedIn Learning. If, like us, you believe in the power of science to address some of the most challenging diseases of our time, then youll fit right in as we search for the next breakthroughs in biopharma. There are no upcoming events. Yield Attractiveness B 3.27% forward dividend yield. Note to new hires: Access to enrollment site will begin 3-5 days after your hire date. %%EOF These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Bristol-Myers Squibb's shares . We are committed to following all laws regarding child labor, forced labor and freedom of association. FDA MedWatch at 1-800-FDA-1088, and Celgene Corporation, a Bristol-Myers Squibb Company, at 1-888-423-5436. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. Monday Jan 11, 2021 07:30 AM ET. (PDF). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges or other income resulting from up-front or contingent milestone payments in connection with the acquisition or licensing of third-party intellectual property rights, divestiture gains or losses, stock compensation resulting from accelerated vesting of Celgene awards, certain retention-related employee compensation charges related to the Celgene transaction, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments beginning in 2021) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items.